Next Generation Kinase Inhibitor Summit 2022

AUM Biosciences’ Co-Founder and CMO, Harish Dave will be presenting at the inaugural Next Generation Kinase Inhibitor Summit 2022. This event brings together experts across drug discovery, preclinical and clinical development who are committed to the innovation and development of kinase inhibitors to overcome resistance.

AUM Biosciences, a clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology, is excited to announce Harish Dave, Co-Founder and CMO, will present our selective pipeline at this summit from 29th to 30th March 2022 in Boston

To learn more about this, please click HERE

About AUM Biosciences

AUM Biosciences is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. The management team has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and have contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability, and scalability.

For more information, please visit